Rare disease pharmacy PANTHERx Rare announced on Friday that it is chosen by California-based Soleno Therapeutics as the specialty pharmacy for the distribution of VYKAT XR (diazoxide choline extended-release tablets).
VYKAT XR is a once daily oral tablet indicated for the treatment of hyperphagia in individuals four years of age and older with Prader-Willi syndrome (PWS). It is the first and only FDA-approved treatment for hyperphagia in individuals with PWS.
Bansi Nagji, PANTHERx CEO, said, 'We are pleased to be selected by Soleno Therapeutics for the distribution of VYKAT XR, the first and only FDA-approved treatment for hyperphagia in individuals with PWS. We believe this medicine has the potential to make a meaningful difference in the lives of the individuals suffering from this rare disease and we look forward to supporting individuals living with PWS and their families in accessing this important therapy.'
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval